Sickle cell disease: a review.
The substitution of one amino acid in the hemoglobin molecule results in sickle hemoglobin. As a result, RBCs sickle in low oxygen states causing occlusion of blood vessels, increased viscosity, and inflammation. These RBCs are prematurely removed from the circulation, resulting in a chronic hemolytic anemia. With newborn screening and early treatment, the death rate among children with SCD has declined. In addition, a variety of treatments are being introduced to help manage the various manifestations of disease. Transfusion, simple or exchange, is a mainstay of therapy, since it reduces the amount of Hgb S in circulation and suppresses erythropoiesis. Transfusion is indicated for symptomatic anemia and specifically to prevent stroke (first or recurrent), during acute stroke, and for acute chest syndrome. Unfortunately, transfusion carries risks for infectious disease transmission, as well as immunologic and inflammatory sequelae. For patients with SCD who may be chronically transfused, iron overload occurs frequently. In addition, due to differences in RBC antigens between donors and recipients, these patients are at increased risk for development of RBC alloantibodies, which can complicate further transfusion. It is, therefore, important to prevent alloimmunization by transfusing leukoreduced RBCs that match the patient for the C, E, and K1 antigens. Human progenitor cell (from bone marrow, peripheral blood stem cells, or umbilical blood) transplant can cure the disease, and is used for patients with severe disease for whom conventional therapy may not be effective.
Roseff
S D
SD
Virginia Commonwealth University, Department of Pathology, Richmond, VA 23298-0662, USA.
D000755:Anemia, Sickle Cell / Q000097:blood / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D001789:Blood Group Antigens / Q000276:immunology*; D001788:Blood Grouping and Crossmatching; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D004913:Erythrocytes, Abnormal / Q000276:immunology / Q000473:pathology; D006454:Hemoglobins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood; D017410:Practice Guidelines as Topic; D013256:Steroids / Q000627:therapeutic use
D001789:Blood Group Antigens; D006454:Hemoglobins; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; D013256:Steroids